Horizon Kinetics Asset Management LLC Salarius Pharmaceuticals, Inc. Transaction History

Horizon Kinetics Asset Management LLC

  • $5.3 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.17 - $41.34 $3,400 - $826,800
20,000 Added 50.0%
60,000 $12,000
Q2 2022

Aug 05, 2022
BUY
$0.16 - $0.42 $6,400 - $16,800
40,000 New
40,000 $8,000

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $3.37M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Horizon Kinetics Asset Management LLC Portfolio

Follow Horizon Kinetics Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Horizon Kinetics Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Horizon Kinetics Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email